The company is dedicated to providing early-stage drug development CRO services to global innovative drug research institutions, focusing on "complex protein preparation as the foundation and structural biology as the core competitiveness." This promotes structure-based drug discovery (SBDD) and aims to establish an international brand in the field of structural biology.

The company boasts internationally renowned protein sample preparation and biological structure analysis technologies. It has assembled a strong team led by experienced leaders, making it a benchmark enterprise with comprehensive service capabilities from gene to cryo-electron microscopy (Cryo-EM) structure analysis. The company's clients span major biopharmaceutical hubs in Boston, San Francisco, San Diego, and New Jersey in the United States, as well as dozens of partners across the Americas, Europe, and Asia, including both major international pharmaceutical companies and emerging biotech firms.

Additionally, the company is collaborating with the Wuxi International Life Science Innovation Park to build a cutting-edge source innovation drug incubator, establishing two innovation centers to further provide a rich array of services to innovative drug companies. The Cryo-EM Innovation Center focuses on "single-particle analysis (SPA) of complex proteins" and "MicroED small molecule structure and crystal form identification." The Drug Target Protein Innovation Center emphasizes membrane protein research, virtual screening, and hit compound screening. These centers will be open to innovative drug companies and research institutions both domestically and internationally, delivering high-quality services to create value for source innovation clients.